Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Curto-Barredo, Laiaca
• dc.contributor.author Duran Jordà, Xavier, 1974-ca
• dc.contributor.author Giménez Arnau, Anna Mariaca
• dc.date.accessioned 2018-10-22T07:33:52Z
• dc.date.issued 2018
• dc.format.mimetype application/pdf
• dc.identifier.citation Curto-Barredo L, Spertino J, Figueras-Nart I, Expósito-Serrano V, Guilabert A, Melé-Ninot G. et al. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticarial. Br J Dermatol. 2018 Jul;179(1):210-212. DOI: 10.1111/bjd.16379
• dc.identifier.doi http://dx.doi.org/10.1111/bjd.16379
• dc.identifier.issn 0007-0963
• dc.identifier.uri http://hdl.handle.net/10230/35625
• dc.language.iso eng
• dc.publisher Wiley-Blackwellca
• dc.relation.ispartof British Journal of Dermatology. 2018 Jul;179(1):210-2
• dc.rights This is the pre-peer reviewed version of the following article: urto-Barredo L, Spertino J, Figueras-Nart I, Expósito-Serrano V, Guilabert A, Melé-Ninot G. et al. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticarial. Br J Dermatol. 2018 Jul;179(1):210-212., which has been published in final form at http://dx.doi.org/10.1111/bjd.16379. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.subject.other Urticària -- Tractament
• dc.title Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticariaca
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/acceptedVersion